NSCLC

Browse all NSCLC
Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

NSCLC

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

NSCLC

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

ASCO 2025: Key Clinical Trials in Resectable NSCLC

NSCLC

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MD, Mitchell Alexander Parma, MD

Tailoring Treatment for Patients With EGFR-Positive NSCLC

NSCLC

Tailoring Treatment for Patients With EGFR-Positive NSCLC

Chinmay Jani, MD, Coral Olazagasti, MD

SCLC

Browse all SCLC
Small Cell Lung Cancer Takes Center Stage at ASCO 2025

SCLC

Small Cell Lung Cancer Takes Center Stage at ASCO 2025

Eric Singhi, MD, Sandip Patel, MD, FASCO

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

SCLC

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

Eric Singhi, MD, Sandip Patel, MD, FASCO